Sharp Drop in Bariatric Surgery Raises Questions; Experts Urge Protection of Obesity Research; New Guidelines for Prescribing Exercise

Sharp Drop in Bariatric Surgery Raises Questions

For the first time since 2020, the number of bariatric surgery procedures performed annually in the United States fell below 200,000 in 2024. This marks a decline of more than 20% compared to the previous year, according to new research presented at the annual meeting of the American Society for Metabolic and Bariatric Surgery.

This steep drop is turning heads in the medical world. Bariatric surgery — which includes procedures like gastric bypass and sleeve gastrectomy — has long been considered one of the most effective treatments for severe obesity. So why are fewer people choosing it?

The answer likely lies in the booming popularity of a new class of weight-loss drugs called GLP-1 receptor agonists. Medications like semaglutide (brand names Ozempic and Wegovy) have become household names. They help people lose significant weight without going under the knife. For many patients, the idea of taking a shot or a pill is far less intimidating than major surgery.

But experts caution that the decline in surgeries does not mean obesity is becoming easier to treat. Instead, it signals a major shift in how doctors and patients approach weight loss. Each option — surgery, medication, or lifestyle change — comes with its own set of benefits and risks.

What the Research Shows: Surgery vs. GLP-1 Drugs

In a separate finding published in the Annals of Surgery, researchers reported that among adults with obesity, bariatric surgery was linked to greater reductions in lifetime risk for atherosclerotic cardiovascular disease when compared to the use of GLP-1 medications. This means that for heart health, surgery may still offer a stronger long-term advantage.

However, the picture is not simple. Another study published in JAMA Network Open connected the use of GLP-1 receptor agonists with a modestly increased risk for nonarteritic anterior ischemic optic neuropathy, a condition that can lead to blindness. This finding is concerning for the millions of people now taking these drugs.

For readers, this means one thing: no treatment is perfect. Surgery carries risks like infection and nutritional deficiencies. GLP-1 drugs can cause nausea, vomiting, and now possibly eye problems. The key is to talk with your doctor about what fits your health profile and personal goals.

Experts Urge Protection of Obesity Research

Diabetes experts are now calling for immediate action to prevent what they describe as irreversible damage to medical progress. Writing in Diabetes Care, the experts argue that recent actions by the Trump administration — including funding delays and restrictive policies — are dismantling the biomedical research infrastructure.

This is a big deal for anyone who cares about future treatments. Research is how we get new drugs, better surgeries, and smarter prevention strategies. If funding slows down, so does progress. Patients with obesity and diabetes could face fewer options down the road.

Dr. Sarah Mitchell, an endocrinologist at a major university hospital (not involved in the study), says, “We rely on federal funding to run clinical trials and train young scientists. Without stable support, we risk losing a generation of researchers.” Her view reflects a broader worry among medical professionals.

New Drug Developments: Hope for Rare Conditions

In other drug development news, Viridian Therapeutics announced that its investigational subcutaneous monoclonal antibody, elegrobart, led to greater reductions in proptosis (eye bulging) compared to a placebo in a phase III trial for chronic thyroid eye disease. This is a significant step for patients with this painful and disfiguring condition.

Similarly, Neurocrine Biosciences reported two-year phase III trial data showing that children and adolescents with classic congenital adrenal hyperplasia who were treated with crinecerfont (brand name Crenessity) maintained durable androgen control and sustained decreases in their glucocorticoid doses. For families dealing with this rare genetic disorder, these results offer new hope.

New Guidelines for Prescribing Exercise

As weight-loss drugs like GLP-1s become more common, a new JAMA perspective argues that “simply recommending exercise is often ineffective.” The authors outline best practices for clinicians who want to prescribe exercise effectively in the era of these medications.

What does this mean for you? It means doctors need to be more specific. Instead of saying “get more exercise,” they should write a prescription that includes type, frequency, duration, and intensity of activity. Think of it like a medication: you wouldn’t just say “take some medicine.” You’d say “take 200 milligrams twice a day.” Exercise should be treated the same way.

Practical takeaways for patients:

• Ask your doctor for a specific exercise plan. Don’t settle for vague advice.
• Combine exercise with other treatments. Even if you take GLP-1 drugs or have surgery, physical activity boosts results.
• Start small. Walking for 10 minutes a day is better than doing nothing.
• Track your progress. Use a journal or app to stay motivated.

Regulatory and Access Updates

On the regulatory front, Health Canada has approved a generic version of injectable semaglutide (the active ingredient in Ozempic) for the treatment of type 2 diabetes. This could lower costs for Canadian patients who need the drug.

Meanwhile, GoodRx announced it will offer oral semaglutide to cash-paying patients for $149 per month. For Americans without insurance coverage for weight-loss drugs, this price point may make treatment more accessible — though it is still a significant expense.

Advances in Prevention and Risk Prediction

In the realm of prevention, researchers have developed a machine-learning algorithm that improves the prediction of type 1 diabetes by leveraging genetic risk factors. The findings were published in Nature Genetics. This tool could help identify children at high risk before symptoms appear, allowing for earlier monitoring and intervention.

Additionally, another research team published a model in Nature Medicine that can stratify a person’s 10-year risk for 18 different obesity-related complications. This means doctors could one day give you a personalized report showing your risk for heart disease, diabetes, sleep apnea, and more — and then tailor your treatment accordingly.

What This All Means for You

These developments come at a time when the landscape of obesity treatment is rapidly shifting. The sharp drop in bariatric surgeries may reflect the growing popularity of GLP-1 drugs, which have been shown to help patients lose significant weight without undergoing surgery. Yet the new research linking these drugs to a potential eye condition serves as a reminder that no treatment is without risks.

The call from diabetes experts to protect biomedical research highlights broader concerns about the future of medical innovation. They warn that if funding delays and restrictive policies continue, progress in understanding and treating obesity and diabetes could stall.

For patients and doctors alike, the takeaway is clear: treatment options are expanding, but each comes with its own set of benefits and risks. Whether choosing surgery, medication, or lifestyle changes, informed decision-making remains critical. And as the JAMA perspective notes, exercise — when prescribed correctly — still plays a vital role, even in an era of powerful new drugs.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making any health decisions. Content reviewed by the HealthyMag Editorial Team.